[7]Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.ASCO 2022,...
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid July 2024, in the section “Information for Presenters”. Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submi...
Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid July 2024, in the section “Information for Presenters”. Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submi...
[7]Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.ASCO 2022, Abstract 1071 [8]Health-related quality of life (HRQoL) in the AS...
2024ESMO指南更新: SG获ESMO-MCBS最高评分 2024年,ESMO转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将戈沙妥珠单抗(SG)治疗转移性三阴性乳腺癌(mTNBC)的ESMO临床获益量表(ESMO-MCBS)评分,由既往的4分调整为最高等级5分[1-2];目前,SG是mTNBC二线治疗唯一的首选推荐(...
提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers Neuroendocrine and Endocrine cancers Public Policy and Patient Advocacy ...
提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers Neuroendocrine and Endocrine cancers Public Policy and Patient Advocacy ...
2024;42(15):1738-1744. doi:10.1200/JCO.23.01409 [7]Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.ASCO 2022, Abstract 1071 [8...
[4]Cao dan,et al.Updated results of Surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial.2024 ESMO Abstract#1155P. [5]崔英杰,杨洁,刘梅,等. 治疗神经内分泌肿瘤新型酪氨酸激酶抑制剂索凡替...
[3] 3. Berghmans T, Durieux V, Hendriks LEL, et al. Immunotherapy: from advanced NSCLC to early stages, an evolving concept[J] . Front Med ( Lausanne) , 2020, 7: 90. [4] 2024 ESMO Abstract # 1372. 排版:晓敏